Savara Inc (SVRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Savara Inc (SVRA) has a cash flow conversion efficiency ratio of -0.239x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.53 Million) by net assets ($94.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Savara Inc - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Savara Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Savara Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Savara Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Axis Real Estate Investment Trust
KLSE:5106
|
0.024x |
|
HTC Corp
TW:2498
|
-0.016x |
|
Xi'an Manareco New Materials Co.Ltd
SHG:688550
|
0.045x |
|
U Blox Holding AG
SW:UBXN
|
0.020x |
|
Dynavox Group
ST:DYVOX
|
0.221x |
|
Pennant Group Inc
NASDAQ:PNTG
|
0.056x |
|
Shenzhen Absen Optoelectronic Co Ltd
SHE:300389
|
0.210x |
|
Taiwan Cogeneration Corp
TW:8926
|
0.116x |
Annual Cash Flow Conversion Efficiency for Savara Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of Savara Inc from 2000 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $171.45 Million | $-89.09 Million | -0.520x | -42.85% |
| 2023-12-31 | $140.37 Million | $-51.06 Million | -0.364x | -13.46% |
| 2022-12-31 | $107.78 Million | $-34.55 Million | -0.321x | -15.58% |
| 2021-12-31 | $144.50 Million | $-40.08 Million | -0.277x | +55.17% |
| 2020-12-31 | $64.38 Million | $-39.84 Million | -0.619x | -39.45% |
| 2019-12-31 | $101.70 Million | $-45.12 Million | -0.444x | -- |
| 2018-12-31 | $0.00 | $-39.27 Million | x | -- |
| 2017-12-31 | $119.31 Million | $-28.23 Million | -0.237x | -201.43% |
| 2016-12-31 | $-35.88 Million | $-8.37 Million | 0.233x | +116.92% |
| 2015-12-31 | $23.89 Million | $-32.95 Million | -1.379x | -228.28% |
| 2014-12-31 | $58.66 Million | $-24.64 Million | -0.420x | -12.91% |
| 2013-12-31 | $47.81 Million | $-17.79 Million | -0.372x | -11.72% |
| 2012-12-31 | $41.79 Million | $-13.92 Million | -0.333x | -40.42% |
| 2011-12-31 | $56.78 Million | $-13.47 Million | -0.237x | +24.12% |
| 2010-12-31 | $26.69 Million | $-8.34 Million | -0.313x | +83.47% |
| 2009-12-31 | $6.67 Million | $-12.62 Million | -1.891x | +52.35% |
| 2008-12-31 | $6.00 Million | $-23.79 Million | -3.968x | -526.87% |
| 2007-12-31 | $31.03 Million | $-19.64 Million | -0.633x | +19.92% |
| 2006-12-31 | $19.96 Million | $-15.77 Million | -0.790x | -153.12% |
| 2005-12-31 | $-7.83 Million | $-11.65 Million | 1.488x | +456.18% |
| 2004-12-31 | $12.39 Million | $-5.18 Million | -0.418x | +23.41% |
| 2003-12-31 | $4.12 Million | $-2.25 Million | -0.545x | -142.20% |
| 2002-12-31 | $-852.73K | $-1.10 Million | 1.292x | -51.78% |
| 2001-12-31 | $-638.49K | $-1.71 Million | 2.680x | +1922.59% |
| 2000-12-31 | $14.61 Million | $-2.15 Million | -0.147x | -- |
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.